Safety and Efficacy of EGEN-001 Combined With Carboplatin and Docetaxel in Recurrent, Platinum-Sensitive, Ovarian Cancer

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
EGEN, Inc.
ClinicalTrials.gov Identifier:
NCT00473954
First received: May 15, 2007
Last updated: March 25, 2013
Last verified: March 2013
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been completed.
  Study Completion Date: November 2009
  Primary Completion Date: November 2009 (Final data collection date for primary outcome measure)